In our initial targeted markets of North America, Europe, Australia/New Zealand and Japan, 20-30% of breast cancer lumpectomy surgery patients undergo avoidable 2nd surgeries. We exist to help correct that through the novel use of the gold standard in hospital imaging, intraoperative MRI.